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Multiple studies have shown that antecedent diseases are less prevalent in amyotrophic 
lateral sclerosis (ALS) patients than the general age-matched population, which sug-
gests possible neuroprotection. Antecedent disease could be protective against ALS 
or, conversely, the asymptomatic early physiological underpinnings of ALS could be 
protective against other antecedent disease. Elucidating the impact of antecedent dis-
ease on ALS is critical for assessing diagnostic risk factors, prognostic outcomes, and 
intervention timing. The objective of this study was to examine the relationship between 
antecedent conditions and ALS onset age and disease duration (i.e. survival). Medical 
history surveys for 1439 Emory ALS Clinic patients (Atlanta, GA, USA) were assessed 
for antecedent hypertension, hyperlipidemia, diabetes, obesity, asthma, arthritis, chronic 
obstructive pulmonary disease (COPD), thyroid, kidney, liver, and other non-ALS neuro-
logical diseases. The ALS onset age and disease duration are compared between the 
antecedent and non-antecedent populations using chi square, Kaplan–Meier, and ordi-
nal logistic regression. When controlled for confounders, antecedent hypertension (high 
blood pressure), hyperlipidemia (high cholesterol), arthritis, COPD, thyroid disease, and 
non-ALS neurological disease are found to be statistically associated with a delayed ALS 
onset age, whereas antecedent obesity [body mass index (BMI) > 30] was correlated to 
earlier ALS onset age. With the potential exceptions of liver disease and diabetes (the 
latter without other common comorbid conditions), antecedent disease is associated 
with overall shorter ALS disease duration. The unique potential relationship between 
antecedent liver disease and longer ALS disease duration warrants further investigation, 
especially given liver disease was found to be a factor of 4–7 times less prevalent in ALS. 
Notably, most conditions associated with delayed ALS onset are also associated with 
shorter disease duration. Pathological homeostatic instability exacerbated by hypervigi-
lant regulation (over-zealous homeostatic regulation due to too high regulatory feedback 
gains) is a viable hypothesis for explaining the early-life protection against antecedent 
disease and the overall lower antecedent disease prevalence in ALS patients; the later 
ALS onset age in patients with antecedent disease; and the inverse relationship between 
ALS onset age and disease duration.
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inTrODUcTiOn
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegen-
erative disease with a relatively unknown etiology. Only 5–10% 
of the ALS population can be attributed to familial factors (1), 
while the rest are sporadic. Existing research has found several 
factors that impact disease duration and age of onset of ALS in 
patients. Onset age has been found to occur earlier in those of 
Asian race or male gender (2, 3). Shorter disease duration is 
related to patients who have a later onset age of ALS symptoms 
(2, 4–6).
Many times, those diagnosed with ALS have previously led 
healthy and active lifestyles (7, 8). In fact, it has been repeatedly 
shown that ALS patients have lower rates of antecedent disease 
than that of the general public (9–11). Our prior foundational 
study comprehensively assessing the prevalence of antecedent 
disease found that arthritis, non-ALS neurological disease, liver 
disease, chronic obstructive pulmonary disease (COPD), kidney 
disease, asthma, diabetes, hypertension, obesity, and hyper-
lipidemia were all statistically less prevalent in ALS compared 
to age-, gender-, and geography-matched control patients (11). 
Thyroid disease was qualitatively less but statistically similar to 
the matched control population (11). Lower overall prevalence of 
antecedent disease in ALS populations suggests possible hypoth-
eses of neuroprotection. That is, antecedent disease could be 
protective against ALS, or conversely, the early or asymptomatic 
pathophysiological underpinnings of ALS could be protective 
against other antecedent diseases (11).
While there is a general consensus that antecedent disease is 
less prevalent in ALS, the actual impact of antecedent disease on 
ALS disease duration is more controversial (9, 12–15). Smaller 
studies examining the relationship of antecedent diseases to 
ALS survival have had varied results, including positive (15–17), 
neutral (9, 13), or negative (5) effects on survival duration of 
ALS in patients. Interestingly, the results of studies assessing the 
relationship between antecedent disease and ALS onset age have 
been more consistent, finding that ALS patients with antecedent 
disease generally have a later onset age (9, 12). Here, we perform 
the first large-scale (n = 1439 ALS patients) study to examine if 
multiple types of antecedent conditions affect ALS diagnosis age 
and disease duration.
MaTerials anD MeThODs
A case–control study of antecedent conditions on ALS onset 
or diagnosis age and disease duration of an ALS popula-
tion was performed. The ALS population consisted of 1439 
patients from the Emory ALS Clinic, in Atlanta, GA, USA, 
confirmed to have ALS at their first clinic visit by a board-
certified neurologist via the use of exclusionary diagnostic 
criteria (MRI, blood tests, electrophysiology, CSF, etc.) and/or 
in-clinic physical exam. The Internal Review Boards of Emory 
University, Georgia Institute of Technology, and Georgia State 
University approved this study. Due to the nature of this ret-
rospective study, patient consent was waived by the Internal 
Review Boards.
antecedent conditions
The antecedent presence of hypertension (high blood pressure), 
hyperlipidemia (high blood serum cholesterol, also called dys-
lipidemia), diabetes, obesity, arthritis, asthma, COPD, thyroid 
disease, neurological disease (excluding ALS), kidney disease, 
and liver disease were assessed at the first ALS clinic visit by 
trained medical personnel using a standardized comprehensive 
medical history patient entry survey. Additional information 
for gathering the data can be seen in our previously pub-
lished work, which laid the foundation for the current study 
(11, 18).
study Populations
A total of 1439 confirmed ALS patients were included in the 
study. The control population consisted of 600 confirmed ALS 
patients who had none of the assessed antecedent conditions 
at ALS onset. The antecedent conditions population consisted 
of 839 confirmed ALS patients who had at least one anteced-
ent condition at the ALS onset. Given that all patients had a 
recorded ALS onset age, all 1439 patients were included in 
the ALS onset age study group (600 control patients and 839 
antecedent disease patients). Of the 1439 patients in the ALS 
onset age study group, 787 patients had a recorded date of death 
and were additionally included in the ALS disease duration 
study group (354 control patients and 433 antecedent disease 
patients).
statistical analysis
All statistical tests were completed using SAS 9.3. Chi square 
analysis was done to compare the distributions of the control 
population and antecedent condition population for both out-
comes of interest. For the age of onset and disease duration, the 
chi square compared the distribution above and below the mean. 
Additional chi square analysis was done looking at the extremities 
of the population. This method was utilized to assess the potential 
impact of patient age on the findings. That is, we assessed whether 
younger or older ALS patients have a different distribution. For 
the age of onset, the chi square compared the distribution above 
and below the middle standard deviation (SD) of onset age of the 
entire population or those who were either older than 66.4 years 
or younger than 53.9  years. Chi square analysis compared the 
disease duration distribution above and below the middle SD of 
disease duration in a subset of the total population or outside the 
range of 1.1–3.2 years.
Kaplan–Meier curves showed the disease duration for a 
qualitative assessment. Specifically, the Kaplan–Meir curves plot 
the survival probability versus disease duration (in years) for 
the antecedent and control subgroups within the ALS disease 
duration study population. All individual antecedent conditions, 
along with groupings of conditions, were analyzed.
Ordinal logistic regression was completed for both age of onset 
and disease duration to assess for confounders and compare the 
antecedent conditions with known risk factors. This was done to 
examine what extent each of the antecedent conditions and other 
factors related to the age of onset and disease duration.
TaBle 1 | Demographics of emory clinic als population by als age of onset and disease duration.
Population characteristics Onset age group Disease duration groupa
Overall control Disease Overall control Disease
N 1439 600 839 787 354 433
Ageb,d
Mean (SD) 60.1 (12.5) 56.0 (13.4) 63.1 (11.0) 61.2 (12.4) 57.1 (13.3) 64.6 (10.5)
Disease duration (years)
Mean (SD)d – – – 2.1 (2.1) 2.4 (2.3) 1.9 (1.9)
Genderc% (N)
Maled 60.0 (864) 63.2 (379) 57.8 (485) 57.7 (454) 62.7 (222) 53.6 (232)
Femaled 40.0 (575) 36.8 (221) 42.2 (354) 42.3 (333) 37.3 (132) 46.4 (201)
Race% (N)
Caucasian 57.4 (826) 56.5 (339) 58.3 (489) 59.1 (465) 56.5 (200) 61.2 (265)
African-American 12.3 (177) 12.3 (74) 12.3 (103) 10.7 (84) 10.7 (38) 10.6 (46)
Other 30.2 (434) 31.2 (187) 29.6 (247) 30.2 (238) 32.8 (116) 28.2 (122)
Antecedent conditions% (N)
Hypertension 36.9 (531) – 63.3 (531) 35.8 (282) – 65.1 (282)
Hyperlipidemiac 26.3 (378) – 45.1 (378) 24.0 (189) – 43.6 (189)
Diabetesc 9.0 (129) – 15.4 (129) 7.9 (62) – 14.3 (62)
Obesityc 9.1 (131) – 15.6 (131) 7.2 (57) – 13.2 (57)
Arthritis 5.1 (74) – 8.8 (74) 5.0 (39) – 9.0 (39)
Asthma 4.9 (71) – 8.5 (71) 4.8 (38) – 8.8 (38)
COPD 3.1 (45) – 5.4 (45) 2.8 (22) – 5.1 (22)
Thyroid 6.2 (90) – 10.7 (90) 6.1 (48) – 11.1 (48)
Neurological disease 0.8 (11) – 1.3 (11) 1.0 (8) – 1.8 (8)
Kidney disease 0.8 (12) – 1.4 (12) 1.3 (10) – 2.3 (10)
Liver disease 0.8 (12) – 1.4 (12) 0.9 (7) – 1.6 (7)
The overall study population consisted of 1439 ALS patients (600 control patients and 839 antecedent disease patients). All ALS patients were included in the onset age group. The 
subset of patients in the ALS onset age that had a recorded date of death was also included in the disease duration group.
aDisease duration population is a subgroup of diagnosis age population.
bAge at first visit to clinic.
cAge of onset population significantly different than disease duration population (p < 0.05).
dControl population significantly different than antecedent condition population (p < 0.05).
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For both models, male gender and Caucasian race were set 
as the reference group. Race was assessed as Caucasian, African-
American, and other. The ordinal logistic regression for age of 
onset included all antecedent conditions, race, and gender. The 
ordinal logistic regression for disease duration included all ante-
cedent conditions, race, gender, and age of onset.
resUlTs
We present the demographics and statistical assessment of the 
association of antecedent disease with ALS onset age or disease 
duration in a population of 1439 ALS patients using chi square, 
Kaplan–Meier, and ordinal logistic regression.
Demographics
The ALS onset age study group (consisting of those who had a 
confirmed ALS diagnosis and recorded ALS onset age) has 60% 
males and 40% females, with 58% of the population having at 
least one antecedent condition. The ALS disease duration study 
group (consisting of those with a confirmed ALS diagnosis, 
recorded onset age, and recorded date of death) has 57.7% 
males and 42.3% females, along with 55% having at least one 
antecedent condition. Gender falls on a more equal distribution 
the disease duration group compared to the onset age group 
(p <  0.05). All of the antecedent conditions except hyperlipi-
demia, diabetes, and obesity occur within the same distribution 
between both groups (see Table 1 for additional demographic 
information).
The ALS onset age study group has a diagnosis age mean of 
60.1 years with a SD of 12.5 years. The mean diagnosis age among 
the control population was 56.0 years, males at 54.4 years, and 
females at 58.9  years of age. Those with antecedent conditions 
had an average of 63.1 years, males at 62.4 years, and females at 
64.1 years of age. As has been previously shown, a substantially 
greater proportion of individuals with antecedent conditions are 
older when compared to those without antecedent conditions of 
interest (p < 0.0001).
The ALS disease duration study group has an average disease 
duration of 2.1 years with a SD of 2.1 years. Those without ante-
cedent conditions of interest have an average duration of 2.4 years 
with males at 2.5 years and females at 2.3 years, respectively. Those 
with antecedent conditions have disease duration of 1.9  years 
with males at 2.0 years and females at 1.8 years, respectively. The 
antecedent condition group had a substantially shorter disease 
duration when compared with those without antecedent condi-
tions (p < 0.0001).
TaBle 2 | The effect of individual antecedent conditions on als age of onset and disease duration determined from chi square analysis.
Population age of onset Disease duration
Mean (sD) Nb p-value Mean (sD) Nb p-value
controla 56.0 (13.4) 1439 <0.0001 2.4 (2.3) 787 <0.0001
antecedent condition
Hypertension
Sole 63.2 (10.5) 787 <0.0001 1.9 (1.9) 461 0.0129
Multiple 64.3 (10.5) 1131 <0.0001 1.8 (1.7) 636 <0.0001
Hyperlipidemia
Sole 62.4 (10.0) 687 <0.0001 2.0 (1.5) 390 0.1700
Multiple 65.3 (10.2) 978 <0.0001 1.7 (1.5) 543 <0.0001
Diabetes
Solec 50.9 (14.4) 612 0.1439 3.3 (3.0) 362 1
Multiple 63.9 (10.1) 729 <0.0001 1.7 (1.7) 416 0.0069
Obesity
Sole 52.7 (9.7) 634 0.0767 1.6 (0.9) 369 0.4872
Multiple 57.3 (11.0) 731 0.1771 1.7 (1.2) 411 0.0411
Asthma
Sole 55.1 (12.0) 620 0.4330 3.1 (2.1) 366 0.0947
Multiple 61.1 (12.1) 671 0.0288 2.3 (1.7) 392 0.7308
Arthritis
Soled 59.8 (8.9) 618 0.3314 2.3 (2.3) 363 0.7391
Multiple 65.6 (8.4) 674 <0.0001 1.8 (1.9) 393 0.0435
COPD
Soled 60.7 (16.6) 614 0.1614 2.8 (4.2) 359 1
Multiple 64.3 (11.8) 645 <0.0001 1.9 (2.5) 376 0.5795
Thyroid
Multiple 66.4 (9.6) 690 <0.0001 2.4 (2.7) 402 0.5207
Neurological
Multiplec 68.7 (7.1) 611 0.0006 1.8 (2.1) 362 0.1463
Kidney
Multiplec 69.4 (13.5) 612 0.0706 0.9 (0.6) 364 0.0064
Liver
Multiplec 56.0 (10.9) 612 0.3878 3.5 (3.5) 361 1
Chi square analysis with population distribution above or below the mean of the total population (60.1 for age of onset and 2.12 for disease duration). Mean (SD) is in years, 
represents age of onset or disease duration.
Bold represents statistical significance.
aControl population compared to any antecedent condition population.
bN represents size of population with antecedent condition of interest and control population (no antecedent conditions).
cFisher’s exact test used due to small sample size for age of onset and disease duration.
dFisher’s exact test used due to small sample size for disease duration.
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chi square analysis
Chi square test was used to compare age of onset and disease 
duration between antecedent conditions and those without any 
antecedent conditions. Antecedent condition populations include 
sole condition (only having one antecedent condition of inter-
est), multiple condition (having multiple antecedent conditions, 
including the condition of interest), cardiovascular (having any 
number of the following: hypertension, hyperlipidemia, diabetes, 
or obesity), autoimmune (having any of the following: asthma, 
arthritis, COPD, thyroid disease), and amount (the number of 
antecedent conditions present). For example, a patient with the 
conditions of diabetes and asthma would be located in the multiple 
condition group for asthma and for diabetes, the cardiovascular 
group, the autoimmune group, and the amount group of 2.
Sole and multiple condition populations are found in Table 2. 
Cardiovascular, autoimmune, and amount populations are 
found in Table  3. Mean age of onset and disease duration of 
the antecedent condition populations are reported along with 
the number of patients analyzed for that comparison within the 
tables.
Age of Onset
Hypertension and hyperlipidemia are found to have a substantially 
significant older distribution than the control ALS population as 
the sole antecedent condition and the multiple antecedent condi-
tion (p < 0.0001). A significant later age of onset distribution is 
also found for diabetes, asthma, arthritis, COPD, thyroid diseases, 
and non-ALS neurological diseases in the multiple antecedent 
condition groups (p < 0.05).
In the cardiovascular group, substantial significance for a later 
age of onset distribution is found for all categories except the four 
cardiovascular conditions group (p < 0.001). Autoimmune condi-
tions only show substantial significance with later age of ALS onset 
when other antecedent conditions are also present (p < 0.0001).
TaBle 3 | The effect of antecedent disease categories and number of antecedent diseases on als age of onset and disease duration determined from 
chi square analysis.
antecedent condition age of onset      Disease duration
Mean (sD) N p-value Mean (sD) N p-value
cardiovascular
1 62.8 (11.0) 1014 <0.0001 1.8 (1.9) 572 0.0005
2 64.9 (11.1) 840 <0.0001 1.7 (1.4) 476 0.0016
3 63.6 (8.9) 673 <0.0001 1.6 (1.7) 386 0.0091
4b 63.1 (10.3) 614 0.0523 1.9 (1.2) 362 0.4761
Any 63.5 (10.8) 1341 <0.0001 1.8 (1.7) 734 <0.0001
autoimmune
Sole type 59.8 (11.6) 683 0.1464 2.9 (2.7) 397 0.4189
Multiple types 64.3 (10.8) 849 <0.0001 2.2 (2.3) 486 0.0976
amount of conditions
1 60.9 (11.2) 1007 <0.0001 2.1 (2.1) 565 0.0398
2 65.0 (10.8) 875 <0.0001 1.7 (1.6) 495 0.0008
3 66.4 (9.9) 708 <0.0001 1.3 (1.4) 413 <0.0001
4 63.1 (9.4) 643 0.002 2.1 (1.7) 372 0.4483
5b 65.6 (6.2) 605 0.0592 3.1 (2.4) 358 1
6a,c 65 601 0.2085 – – –
Chi square analysis with population distribution above or below the mean of the total population (60.1 for age of onset and 2.12 for disease duration). Mean (SD) is in years, 
represents age of onset or disease duration.
Bold represents statistical significance.
aSample size of one.
bFisher’s exact test used due to small sample size for age of onset and disease duration.
cFisher’s exact test used due to small sample size for age of onset.
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Up to three antecedent condition groups have a substantially 
significantly older distribution (p < 0.0001). Those with four ante-
cedent conditions have a significant older distribution at onset 
(p < 0.05). There is no significance found for those with five or six 
antecedent conditions, likely owing to small sample size.
Disease Duration
Hypertension, hyperlipidemia, diabetes, obesity, arthritis, and 
kidney disease all have a different distribution than the control for 
multiple antecedent conditions (p < 0.05). The significance found 
shows that those antecedent condition populations have a shorter 
disease duration that the control population. Cardiovascular 
conditions show a difference in disease duration for one, two, 
and three conditions or having any cardiovascular condition at 
all (p < 0.05). Those categories are correlated to shorter disease 
duration when compared to the control population. Antecedent 
conditions of the amounts of one, two, and three result in sub-
stantially shorter disease duration than the control (p <  0.05). 
Significance is not found in those with four or five antecedent 
conditions due to a limiting sample size.
When analysis was repeated with the middle SD omitted for 
the populations, results mirrored those previously reported. 
These findings affirm that the potential confound of age, itself, 
is not substantially skewing the primary results. Thus, the rela-
tionships with ALS onset age and disease duration are similar in 
both the younger antecedent disease ALS patients and the older 
antecedent disease ALS patients.
Kaplan–Meier
Kaplan–Meier graphs resulted in the visualization of several 
different trends. The overall conditions compared to the control 
population showed a diversion in the middle of survival, with 
both groups being near equal at the start and at the tail end of 
survival. Figure  1 shows different trends throughout multiple 
conditions.
The Kaplan–Meier results (Figure 1) denoted four main trends 
for survival. For those with antecedent conditions compared to 
the control, there is a similar survival rate at the beginning and end 
of the survival curve between the two groups. The control popula-
tion exhibited a better survival rate when not at the extremes. This 
trend was seen in the cardiovascular, blood pressure, and choles-
terol groups as well as the antecedent conditions population.
For autoimmune, COPD, and arthritis, there were multiple 
points throughout the survival curve, in which the antecedent 
condition group converged with the control group. Nearly every 
time the curves diverged, antecedent conditions had a lower 
survival rate.
Non-ALS neurological disease and kidney disease were found 
to have a much steeper slope (i.e., lower survival) when compared 
to the control group. The poor results of Kaplan–Meier could 
be due to either small sample sizes or the antecedent condition 
already expediting patient death prior to ALS diagnosis.
Asthma and thyroid disease groups were found to have a very 
similar survival rate and trend compared to the control. Thus, 
asthma and thyroid disease seem to have no effect on ALS disease 
duration.
Liver disease was found to have a qualitatively better ALS sur-
vival duration than the control. Only the diabetes sole group also 
included a qualitatively higher survival duration. Nonetheless, 
neither liver disease nor sole diabetes was found to be statisti-
cally significant in extending disease duration, likely owing to 
sample size.
FigUre 1 | Kaplan–Meier graphs of als disease duration population. (a) Control group (red) compared to those with at least one antecedent condition. 
(B) Control group (red) compared to the obesity sole group. (c) Control group (red) compared to those who have thyroid disease. (D) Control group (red) compared 
to those who have liver disease.
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Ordinal logistical regression
Ordinal logistical regression modeling is used to examine 
the potential confound of patient age on ALS onset age and 
disease duration. Hypertension, hyperlipidemia, arthritis, 
COPD, thyroid disease, non-ALS neurological disease, “other” 
race, and gender were found to be significant variables with an 
association to a delayed age of onset past the mean (60.1 years). 
“African-American” race and obesity are found to have a sig-
nificant association to an earlier age of onset. When looking at 
disease duration, age of onset, and “other” race are significant 
variables associated with shortening disease duration under the 
mean (2.1 years). See Table 4 for the odds ratios for all variables 
tested.
DiscUssiOn
The primary findings of this study support the presence of lower 
overall antecedent disease in ALS, a later onset of ALS in patients 
with antecedent disease, and an inverse relationship between 
onset age and disease duration. We discuss these trends in more 
detail, including the possible exceptions with liver disease and 
obesity, as well as potential protective mechanisms. We contend 
that our findings, combined with current experimental and 
clinical literature, are highly suggestive of the role of hypervigi-
lant regulation and homeostatic instability in ALS, and conclude 
with a detailed explanation.
antecedent conditions on age of als 
Onset
When looking at individual antecedent conditions, every condi-
tion of interest is found to have a later age of onset excluding obe-
sity (see What about Obesity?). Hypertension, hyperlipidemia, 
arthritis, COPD, thyroid disease, and non-ALS neurological 
disease are found to be significant factors associated with a delay 
in ALS age of onset. These conditions have also been found to be 
less prevalent in the ALS population (9, 11, 19).
With the prevalence lower in the ALS population, there may 
be a mechanism in which these antecedent conditions are protec-
tive against ALS in an unknown pathway. Diabetes and hyper-
lipidemia have been previously suggested to be biochemically 
TaBle 4 | Ordinal logistic regression modeling of als age of onset and 
disease duration.
Model         Variable Odds ratio 95% confidence interval
age of onset
Hypertension 0.499 0.391 0.637
Hyperlipidemia 0.416 0.316 0.547
Diabetes 0.799 0.526 1.213
Obesity 1.994 1.335 2.978
Asthma 1.283 0.762 2.16
Arthritis 0.494 0.285 0.855
COPD 0.502 0.256 0.984
Thyroid 0.586 0.357 0.96
Neurological 0.097 0.012 0.813
Kidney 0.529 0.151 1.851
Liver 2.795 0.711 10.992
Race (AA) 1.521 1.07 2.162
Race (other) 0.71 0.553 0.91
Gender (female) 0.64 0.508 0.805
Disease duration
Hypertension 1.156 0.847 1.577
Hyperlipidemia 1.106 0.78 1.569
Diabetes 1.18 0.699 1.992
Obesity 1.106 0.647 1.892
Asthma 0.664 0.353 1.251
Arthritis 0.959 0.51 1.801
COPD 1.42 0.601 3.352
Thyroid 0.809 0.454 1.44
Neurological 1.014 0.264 3.893
Kidney 2.451 0.637 9.439
Liver 0.389 0.093 1.629
Race (AA) 0.691 0.441 1.082
Race (other) 2.016 1.479 2.748
Gender (female) 1.186 0.894 1.575
Age 1.049 1.036 1.062
Parameters include the 11 individual antecedent conditions, race, and gender.
Race reference group is Caucasian. Gender reference group is male. For age of onset 
model, estimates above 1 lower the age of onset. For disease duration, estimates 
above 1 shorten the duration.
Bold represents statistical significance.
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neuroprotective against ALS (3, 19), possibly by protecting 
against the hypothesized ALS hypermetabolic state.
antecedent conditions on als Disease 
Duration
No antecedent conditions are found to be statistically significant 
factors in predicting the disease duration in patients. Some research-
ers have found that cardiovascular conditions are beneficial to ALS 
patients as ALS progresses (16, 20), but further research supports 
that the conditions do not have a significant impact on the actual 
ALS disease duration (9, 13, 21). The shorter disease duration 
found in the antecedent condition groups could be attributed to 
the fact that those groups have a later age of onset. Advanced age is 
known to be a predictor of shorter disease duration (2, 4). Another 
possibility is that hypervigilant regulation (see Hypervigilant 
Regulation and Homeostatic Instability) exacerbates underlying 
pathological instability once ALS onset symptoms appear.
Liver disease, while limited by a small sample size, was 
found to have qualitatively better ALS survival duration than 
the control. Liver disease’s potential association with increased 
survival duration, along with its substantially lower prevalence in 
ALS compared to matched control subjects, is suggestive of the 
liver playing a systemic, and possibly even a protective role, in 
the ALS etiology. In fact, a recent study examining ALS treatment 
with tauroursodeoxycholic acid, a hydrophilic bile acid produced 
in the liver, showed promise (22).
What about Obesity?
Antecedent obesity (antecedent static BMI >30) is the only ante-
cedent condition found in the present study to be a significant 
predictor of a younger age of ALS onset. Interestingly, patients 
with long-term antecedent obesity prior to ALS onset would, by 
definition, not have hypervigilant regulation (see Hypervigilant 
Regulation and Homeostatic Instability), which could explain the 
unique earlier ALS onset age of patients with obesity.
Despite the earlier age of onset, the chi square and Kaplan–
Meier analyses show no positive effects on survival in the present 
study. When other studies have found obesity to be beneficial to 
survival, the variable measured is usually rate of change in BMI 
(5, 23). Other studies have focused on unhealthy weight, taking 
any BMI above 24.9 to be considered of interest, with the effects 
varying as BMI changes (21, 24). Thus, while the rate of BMI 
change over the course of ALS progression appears to be a pre-
dictive measure of disease duration, static assessment of BMI at 
ALS onset is not. Essentially all research results have agreed that 
obesity is less prevalent in ALS patients than the general popula-
tion (11, 21, 24) and, correspondingly, lower BMI is associated 
with ALS (25).
hypervigilant regulation and homeostatic 
instability
The results of this study supports the contention that the asympto-
matic physiological precursors of ALS could actually be protect-
ing against other conditions prior to the onset of ALS symptoms 
(11), analogous to how one S gene infers resistance to malaria 
without pathological consequence, while two copies result in the 
pathological sickle cell anemia phenotype (26). Such a contention 
supports the present study’s primary findings: presence of lower 
overall antecedent disease in ALS, a later onset of ALS in patients 
with antecedent disease, and an inverse relationship between 
onset age and disease duration.
One possible explanatory hypothesis is hypervigilant regula-
tion (11) – the aggressive overreaction of underlying regulatory 
processes to correct imbalances from homeostasis, making them 
“hypervigilant” to perturbation (in control theory, a too-high 
feedback gain). Hypervigilant regulation can quickly compensate 
to correct small imbalances from homeostasis to initially protect 
against a wide variety of antecedent conditions (e.g., obesity, 
hyperlipidemia, etc.) or minimally delay their age of onset. 
However, hypervigilant regulation increases later susceptibility 
to more severe pathological homeostatic instability that could 
directly or indirectly lead to ALS (11). Furthermore, once major 
pathological instability does occur (e.g., ALS), the overreactive 
nature of hypervigilant regulation exacerbates further destabi-
lizing regulatory oscillation, which could easily translate into 
shorter ALS disease or survival durations.
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The physically long motoneurons have already been shown to 
be vulnerable to instability in both physiological and pathological 
ALS animal models, including the presence of destabilizing somatic 
dynamics (27), axonal transport deregulation (28), metabolic 
insufficiency (29), inadequate calcium buffering (29), compensa-
tory oxidative stress responses (29), and dynamic imbalances of 
pro- and anti-inflammatory cytokines (30). Mathematical oscilla-
tions and corresponding instabilities have also been identified in 
theoretical ALS models (31). The multifactorial nature of ALS, as 
shown by the variety of underlying cellular and systemic in vitro 
and in vivo disturbances in transgenic mice (32) and the presence 
of overlapping biomarkers with other neurological diseases (6), 
is also suggestive of system-level instability as a possible primary 
ALS cause.
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